These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 657160)

  • 1. Therapeutic value of mepitiostane in the treatment of advanced breast cancer.
    Inoue K; Okazaki K; Morimoto T; Hayashi M; Uyama S; Sonoo H; Koshiba Y; Takihara T; Nomura Y; Yamagata J; Kondo H; Kanda K; Takenaka K
    Cancer Treat Rep; 1978 May; 62(5):743-5. PubMed ID: 657160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether in the treatment of advanced breast cancer: Japanese Cooperative Group of Hormonal Treatment for Breast Cancer.
    Cancer; 1978 Feb; 41(2):758-60. PubMed ID: 343913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine adjuvant therapy with the antiestrogen, mepitiostane, inoperable breast cancer patients on the basis of estrogen receptor assay.
    Nomura Y; Yamagata J; Kondo H; Takenaka K
    Gan; 1978 Apr; 69(2):281-2. PubMed ID: 680466
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibitory effect of mepitiostane on the growth of mammary tumor of a rat.
    Takatani O; Kumaoka S
    Gan; 1977 Jun; 68(3):337-41. PubMed ID: 913955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer].
    Konstantinova MM; Gershanovich MA
    Vopr Onkol; 1990; 36(10):1182-6. PubMed ID: 2147527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2 ,3 - Epithio-5 -androstan-17 -ol in the treatment of advanced breast cancer.
    Fujimori M
    Cancer; 1973 Apr; 31(4):789-92. PubMed ID: 4574661
    [No Abstract]   [Full Text] [Related]  

  • 8. Antitumor effect of two oral steroids, mepitiostane and fluoxymesterone, on a pregnancy-dependent mouse mammary tumor (TPDMT-4).
    Matsuzawa A; Yamamoto T
    Cancer Res; 1977 Dec; 37(12):4408-15. PubMed ID: 922732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
    Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
    Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)].
    Nomura Y; Nakajima M; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1045-63. PubMed ID: 9644320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New endocrine approaches in the treatment of breast cancer.
    von Minckwitz G; Kaufmann M
    Biomed Pharmacother; 1998; 52(3):122-32. PubMed ID: 9755805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of estrogen receptors in predicting response to antiestrogens.
    Valavaara R
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
    Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormone treatment of breast cancer].
    Gröhn P
    Duodecim; 1991; 107(8):603-10. PubMed ID: 1364913
    [No Abstract]   [Full Text] [Related]  

  • 15. [Early phase II study of TAT-59 in patients with advanced or recurrent breast cancer--a multicenter dose finding study].
    Aoyama H; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 May; 25(6):853-65. PubMed ID: 9617324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent progress in endocrine therapy of patients with breast cancer].
    Tominaga T
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3196-202. PubMed ID: 3058041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
    Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
    Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination].
    Chevallier B; Spielmann M; Marty M; Serin D; Pouillart P; Tubiana Hulin M; Mignot L; Pujade Lauraine E; Krams M; Mertens H
    Bull Cancer; 1993 Jul; 80(7):624-8. PubMed ID: 8204943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New developments in the hormonal treatment of breast cancer in postmenopausal women].
    Trunet P; Marty M
    Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.